Home ETF List About

Portfolio Holdings Detail for ISIN IE00BHZPJ890
Stock Name / FundiShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerEEDG(GBP) LSE
ETF TickerEEDS(USD) LSE
ETF TickerEEDG.LS(GBP) CXE
ETF TickerEEDS.LS(USD) CXE
ETF TickerOM3L.DE(EUR) CXE
ETF TickerEEDG.L(GBP) LSE
ETF TickerEEDS.L(GBP) LSE

Holdings detail for ALNY

Stock NameAlnylam Pharmaceuticals Inc
TickerALNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS02043Q1076
LEI529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist) ALNY holdings

DateNumber of ALNY Shares HeldBase Market Value of ALNY SharesLocal Market Value of ALNY SharesChange in ALNY Shares HeldChange in ALNY Base ValueCurrent Price per ALNY Share HeldPrevious Price per ALNY Share Held
2025-09-29 (Monday)41,122USD 18,401,684USD 18,401,684
2025-09-26 (Friday)41,112USD 18,352,397USD 18,352,397
2025-09-25 (Thursday)41,622ALNY holding increased by 275USD 18,712,419ALNY holding decreased by -239805USD 18,712,419275USD -239,805 USD 449.58 USD 458.37
2025-09-24 (Wednesday)41,347USD 18,952,224USD 18,952,224
2025-09-18 (Thursday)39,443ALNY holding increased by 140USD 17,834,941ALNY holding increased by 80793USD 17,834,941140USD 80,793 USD 452.17 USD 451.725
2025-09-17 (Wednesday)39,303ALNY holding increased by 215USD 17,754,148ALNY holding decreased by -274801USD 17,754,148215USD -274,801 USD 451.725 USD 461.24
2025-09-16 (Tuesday)39,088USD 18,028,949ALNY holding increased by 3909USD 18,028,9490USD 3,909 USD 461.24 USD 461.14
2025-09-15 (Monday)39,088ALNY holding increased by 109USD 18,025,040ALNY holding decreased by -134886USD 18,025,040109USD -134,886 USD 461.14 USD 465.89
2025-09-12 (Friday)38,979ALNY holding increased by 85USD 18,159,926ALNY holding decreased by -65025USD 18,159,92685USD -65,025 USD 465.89 USD 468.58
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BHZPJ890

Show aggregate share trades of ALNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY275 449.580* 286.65
2025-09-18BUY140 452.170* 285.74
2025-09-17BUY215 451.725* 284.83
2025-09-15BUY109 461.140* 282.87
2025-09-12BUY85 465.890* 281.85
2025-09-11SELL-270 468.580* 280.80 Profit of 75,816 on sale
2025-09-10BUY50 469.310* 279.74
2025-09-09BUY65 482.130* 278.59
2025-08-27BUY13,182 454.180* 276.58
2025-08-21BUY6 467.550* 274.43
2025-08-19BUY18 458.280* 272.27
2025-07-21BUY3 320.520* 271.99
2025-07-18BUY141 320.530* 271.70
2025-07-17BUY18 324.690* 271.38
2025-07-16BUY315 322.810* 271.07
2025-07-15BUY165 311.120* 270.83
2025-07-03SELL-24 331.910* 270.08 Profit of 6,482 on sale
2025-07-02SELL-186 329.770* 269.71 Profit of 50,166 on sale
2025-06-30SELL-3 326.090* 269.36 Profit of 808 on sale
2025-06-27BUY12 322.830* 269.02
2025-06-26BUY6 318.250* 268.71
2025-06-25BUY12 321.940* 268.38
2025-06-24SELL-9 325.000* 268.02 Profit of 2,412 on sale
2025-06-17SELL-12 308.710* 266.60 Profit of 3,199 on sale
2025-06-13SELL-6 307.990* 266.04 Profit of 1,596 on sale
2025-06-12BUY9 304.670* 265.78
2025-06-06SELL-42 300.830* 264.79 Profit of 11,121 on sale
2025-06-05SELL-66 308.000* 264.49 Profit of 17,457 on sale
2025-06-04SELL-87 305.310* 264.21 Profit of 22,986 on sale
2025-06-03BUY18 303.770* 263.93
2025-06-02SELL-6 306.090* 263.63 Profit of 1,582 on sale
2025-05-30BUY11,821 304.560* 263.34
2025-05-29SELL-12 292.900* 263.13 Profit of 3,158 on sale
2025-05-28SELL-8 285.560* 262.96 Profit of 2,104 on sale
2025-05-23SELL-36 289.960* 262.36 Profit of 9,445 on sale
2025-05-22BUY2 289.000* 262.16
2025-05-21SELL-10 292.580* 261.94 Profit of 2,619 on sale
2025-05-20BUY44 291.680* 261.71
2025-05-16SELL-18 285.310* 261.30 Profit of 4,703 on sale
2025-05-15BUY2 283.400* 261.12
2025-05-14BUY36 267.550* 261.07
2025-05-13BUY134 266.860* 261.03
2025-05-12BUY106 270.190* 260.96
2025-05-09BUY34 251.150* 261.03
2025-05-08SELL-32 258.350* 261.06 Profit of 8,354 on sale
2025-05-07BUY94 276.550* 260.93
2025-05-06BUY22 269.810* 260.86
2025-05-02SELL-4 259.390* 260.76 Profit of 1,043 on sale
2025-05-01SELL-2 255.130* 260.81 Profit of 522 on sale
2025-04-28SELL-272 254.850* 260.87 Profit of 70,958 on sale
2025-04-25SELL-4 251.560* 260.95 Profit of 1,044 on sale
2025-04-24SELL-62 242.610* 261.12 Profit of 16,189 on sale
2025-04-23SELL-22 241.970* 261.28 Profit of 5,748 on sale
2025-04-22SELL-14 236.750* 261.50 Profit of 3,661 on sale
2025-04-16SELL-78 230.500* 262.56 Profit of 20,479 on sale
2025-04-11BUY38 237.770* 263.31
2025-04-10BUY12 226.280* 263.66
2025-04-09BUY20 243.270* 263.86
2025-04-08SELL-58 224.320* 264.25 Profit of 15,326 on sale
2025-04-07BUY38 232.950* 264.56
2025-04-04BUY86 235.740* 264.85
2025-04-02BUY34 266.830* 264.83
2025-04-01BUY16 255.760* 264.92
2025-03-31SELL-86 270.020* 264.87 Profit of 22,779 on sale
2025-03-28SELL-8 268.460* 264.83 Profit of 2,119 on sale
2025-03-26BUY2 269.210* 264.72
2025-03-25BUY6 280.960* 264.54
2025-03-24BUY12 290.700* 264.26
2025-03-21BUY312 283.340* 264.05
2025-03-19SELL-58 253.440* 264.29 Profit of 15,329 on sale
2025-03-17SELL-4 253.110* 264.64 Profit of 1,059 on sale
2025-03-14SELL-8 241.760* 264.91 Profit of 2,119 on sale
2025-03-13SELL-2 241.750* 265.18 Profit of 530 on sale
2025-03-12SELL-8 242.430* 265.45 Profit of 2,124 on sale
2025-03-11BUY2 238.740* 265.78
2025-03-06BUY124 248.130* 266.67
2025-03-05SELL-10 249.230* 266.89 Profit of 2,669 on sale
2025-03-03BUY6 243.530* 267.51
2025-02-28SELL-10,882 246.750* 267.78 Profit of 2,913,976 on sale
2025-02-27SELL-60 237.100* 268.19 Profit of 16,091 on sale
2025-02-26SELL-759 243.860* 268.52 Profit of 203,805 on sale
2025-02-25SELL-51 245.200* 268.84 Profit of 13,711 on sale
2025-02-24BUY75 248.940* 269.11
2025-02-21BUY39 250.590* 269.37
2025-02-20BUY9 251.000* 269.64
2025-02-19BUY6 250.510* 269.91
2025-02-18SELL-33 250.000* 270.21 Profit of 8,917 on sale
2025-02-14BUY9 256.450* 270.62
2025-02-13SELL-6 264.890* 270.71 Profit of 1,624 on sale
2025-02-12SELL-114 265.960* 270.79 Profit of 30,870 on sale
2025-02-06BUY15 278.250* 270.55
2025-02-05SELL-45 276.310* 270.45 Profit of 12,170 on sale
2025-02-03BUY6 274.550* 270.37
2025-01-30SELL-63 277.160* 270.23 Profit of 17,024 on sale
2025-01-28SELL-39 279.190* 269.99 Profit of 10,529 on sale
2025-01-27BUY18 276.730* 269.86
2025-01-24BUY33 278.760* 269.68
2025-01-23BUY33 275.540* 269.57
2024-12-09BUY6 255.890* 270.18
2024-12-06BUY93 256.260* 270.47
2024-12-04BUY69 254.720* 271.24
2024-12-03BUY39 251.840* 271.68
2024-12-02BUY90 253.010* 272.11
2024-11-29BUY9 253.070* 272.57
2024-11-27BUY3 253.740* 273.51
2024-11-26SELL-102 253.350* 274.57 Profit of 28,006 on sale
2024-11-26SELL-102 253.350* 274.57 Profit of 28,006 on sale
2024-11-25BUY4,868 250.980* 275.21
2024-11-22SELL-5 244.890* 276.05 Profit of 1,380 on sale
2024-11-21BUY126 246.800* 276.88
2024-11-19SELL-27 234.270* 279.03 Profit of 7,534 on sale
2024-11-18BUY60 232.270* 280.49
2024-11-12BUY3 268.950* 280.86
2024-11-08BUY9 277.430* 281.14
2024-11-08BUY9 277.430* 281.14
2024-11-07BUY231 272.220* 281.83
2024-11-07BUY231 272.220* 281.83
2024-11-06BUY6 273.010* 282.56
2024-11-06BUY6 273.010* 282.56
2024-11-05SELL-15 265.290* 284.13 Profit of 4,262 on sale
2024-11-05SELL-15 265.290* 284.13 Profit of 4,262 on sale
2024-11-04SELL-108 269.950* 285.55 Profit of 30,839 on sale
2024-11-04SELL-108 269.950* 285.55 Profit of 30,839 on sale
2024-11-01SELL-30 273.910* 286.84 Profit of 8,605 on sale
2024-11-01SELL-30 273.910* 286.84 Profit of 8,605 on sale
2024-10-31BUY17 266.590* 289.38
2024-10-31BUY17 266.590* 289.38
2024-10-30SELL-114 281.490* 290.50 Profit of 33,117 on sale
2024-10-30SELL-114 281.490* 290.50 Profit of 33,117 on sale
2024-10-29SELL-108 284.690* 291.47 Profit of 31,479 on sale
2024-10-29SELL-108 284.690* 291.47 Profit of 31,479 on sale
2024-10-28BUY9 286.910* 292.38
2024-10-28BUY9 286.910* 292.38
2024-10-25BUY192 284.860* 294.26
2024-10-25BUY192 284.860* 294.26
2024-10-24BUY24 293.690* 294.45
2024-10-24BUY24 293.690* 294.45
2024-10-23SELL-4 294.870* 294.25 Profit of 1,177 on sale
2024-10-23SELL-4 294.870* 294.25 Profit of 1,177 on sale
2024-10-22BUY21 296.480* 292.01
2024-10-22BUY21 296.480* 292.01
2024-10-21SELL-210 292.010* 0.00
2024-10-21SELL-210 292.010* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19216,7273,259396,24354.7%
2025-09-18172,875397386,43244.7%
2025-09-17246,547167472,29252.2%
2025-09-1688,84660226,33639.3%
2025-09-15148,25813,572435,68934.0%
2025-09-12134,122300244,96854.8%
2025-09-11219,8687,820411,70253.4%
2025-09-10543,3267,595916,89859.3%
2025-09-09705,54033,7311,550,89945.5%
2025-09-08175,158440388,71545.1%
2025-09-05127,116335311,25240.8%
2025-09-04110,9302,555236,56846.9%
2025-09-03182,3868,982562,92132.4%
2025-09-02132,77014,416358,47637.0%
2025-08-2993,2162,181276,59433.7%
2025-08-2860,1821,254226,86526.5%
2025-08-27277,6671,084440,57763.0%
2025-08-26243,404919447,42154.4%
2025-08-25156,55115,662374,27641.8%
2025-08-22228,5961,309408,15256.0%
2025-08-21123,9962,862248,30049.9%
2025-08-20149,63813,723316,98347.2%
2025-08-19144,3201,143308,39946.8%
2025-08-18371,31834,264525,78670.6%
2025-08-15104,01813,245265,62039.2%
2025-08-14133,2724,443505,52826.4%
2025-08-13183,2711,3901,017,62318.0%
2025-08-12173,0454,046693,01825.0%
2025-08-11239,1997,600451,24853.0%
2025-08-08168,7553,199466,74436.2%
2025-08-07308,8104,452527,39958.6%
2025-08-06202,15112,590548,34936.9%
2025-08-05256,29513,237826,28331.0%
2025-08-04411,11436,303729,94956.3%
2025-08-01350,06060,108764,94345.8%
2025-07-31829,1916,0231,541,01553.8%
2025-07-30533,88514,703942,78856.6%
2025-07-29164,26855384,53742.7%
2025-07-28150,24069571,96526.3%
2025-07-2590,782429298,80130.4%
2025-07-24132,00111,546286,15546.1%
2025-07-23184,14963312,34059.0%
2025-07-22134,7617,553524,61225.7%
2025-07-21113,303101243,11946.6%
2025-07-1884,1179196,31742.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.